• GAPNA 2020 National President Deborah Dunn, EdD, MSN, GNP-BC, ACNS-BC, GS-C interviews Dr. Ron Billano Ordona, DNP, FNP-BC about providing home-based primary care during COVID 19.

    "Facing Forward: Providing Home-based Primary Care during COVID 19"

    View the Video

  • GAPNA 40th AnniversaryGAPNA’s anniversary theme “Preserve the Past, Enhance the Present, and Secure the Future,” reflects our shared vision for gerontological advanced practice nursing.


    Learn How You Can Help

  • GAPNA Exchange


    GAPNA Exchange is a private, secure community for members to share ideas, ask questions, lend expertise, and network with peers.

    It features both an Open Forum discussion area along with smaller, segmented communities.

    Interact with GAPNA members wherever and whenever!

    Go to GAPNA Exchange

  • CoronaCoronavirus (COVID-19) Resources

    In an effort to support our members with the most updated information on COVID-19 we developed this resource page to easily access current CDC information and other resources to assist you professionally and personally.

    We will continue to update this page with more information as it becomes available and welcome your input as we navigate through this situation. As health care professionals it is our job to educate our patients and families on prevention and the what to do if someone is symptomatic.

    View resources


Elderly Patients with Colon Cancer at Risk for Various Treatment-Related Toxicities

Patients who receive surgery for stage III colon cancer can benefit from 5-flurouracil (5-FU)-based chemotherapy.

However, 5-FU-based chemotherapy is associated with increased risk of developing gastrointestinal, blood, and cardiac toxicities in elderly patients with colon cancer. These patients need to be monitored closely so that the benefits of chemotherapy can outweigh the risks, suggest the study authors.

In a study of 12,099 patients with stage III colon cancer, patients receiving chemotherapy were more likely to be younger, married, and have fewer coexisting conditions than the untreated group.

This difference was most pronounced for age, with 88.2% of patients aged 65-69 initiating chemotherapy compared to just 18.1% of patients aged 85 and older.

During 3 months after surgery, the cumulative incidence rate of toxicities was 9.1% in the chemotherapy group and 4.3% in the non-chemotherapy group.

Common toxicities included volume depletion disorder, agranulocytosis, diarrhea, nausea, and vomiting. Women were 35% more likely to experience toxicities than men and Blacks were 35% less likely to develop toxicities than Whites.

Chemotherapy was only slightly associated with the risk for developing heart disease.

For more info, see Hu, C-Y. et al. (2012). Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer. American Journal of Clinical Oncology, 35(3), 228-236.

Related Topic 1: 

GAPNA Newsletter Issue: